Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups
暂无分享,去创建一个
Erik Olofsen | Albert Dahan | A. Dahan | E. Olofsen | C. Martini | A. Yassen | Ashraf Yassen | Christian Martini | Paul Passier | Malcom Stoker | P. Passier | M. Stoker
[1] P. Blumberg,et al. Vanilloid (Capsaicin) receptors and mechanisms. , 1999, Pharmacological reviews.
[2] R. Hughes,et al. Duloxetine for treating painful neuropathy or chronic pain. , 2009, The Cochrane database of systematic reviews.
[3] J. Ochoa,et al. Early and late effects of prolonged topical capsaicin on cutaneous sensibility and neurogenic vasodilatation in humans , 1991, Pain.
[4] M. Nolano,et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation , 1999, Pain.
[5] L. Webster,et al. Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. , 2011, Diabetes research and clinical practice.
[6] J. Ochoa,et al. Early and Late Effects of Prolonged Topical Capsaicin on Cutaneous Sensibility and Neurogenic Vasodilation in Humans , 1992 .
[7] M. Koltzenburg. Painful neuropathies. , 1998, Current opinion in neurology.
[8] S. Abram. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch , 2012 .
[9] A. Basbaum,et al. The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli , 1998, Neuron.
[10] D. Howes. Sensation , 2011, The Drama of Celebrity.
[11] R. Baron,et al. 262 A CROSS‐SECTIONAL SURVEY IN 2100 PATIENTS WITH PAINFUL DIABETIC NEUROPATHY AND POSTHERPETIC NEURALGIA: DIFFERENCES IN DEMOGRAPHIC DATA AND SENSORY SYMPTOMS , 2010 .
[12] P. Wiffen,et al. Pregabalin for acute and chronic pain in adults. , 2009, The Cochrane database of systematic reviews.
[13] P. Dyck,et al. Pathologic Alterations in the Diabetic Neuropathies of Humans: A Review , 1996, Journal of neuropathology and experimental neurology.
[14] A. Beydoun,et al. Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: a Randomized Controlled Trial , 1999 .
[15] P. Wiffen,et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. , 2011, The Cochrane database of systematic reviews.
[16] D. Julius,et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway , 1997, Nature.
[17] D. Ranoux. [Painful peripheral neuropathy]. , 2008, La Revue du praticien.
[18] Marieke Niesters,et al. Population pharmacokinetic—pharmacodynamic modeling of ketamine‐induced pain relief of chronic pain , 2011, European journal of pain.
[19] Manfred Morari,et al. The Well-being Model: A New Drug Interaction Model for Positive and Negative Effects , 2006, Anesthesiology.
[20] J. Potter,et al. The pathogenesis and management of painful diabetic neuropathy: a review , 2003, Diabetic medicine : a journal of the British Diabetic Association.
[21] A. Vinik. Advances in diabetes for the millennium: new treatments for diabetic neuropathies. , 2004, MedGenMed : Medscape general medicine.
[22] J. Marinus,et al. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1 , 2009, PAIN.
[23] Erik Olofsen,et al. Pharmacokinetic–Pharmacodynamic Modeling of the Effectiveness and Safety of Buprenorphine and Fentanyl in Rats , 2007, Pharmaceutical Research.
[24] Ralf Baron,et al. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms , 2009, PAIN.